About: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 April 2005

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2005 (fr) наукова стаття, опублікована у квітні 2005 (uk) artículu científicu espublizáu n'abril de 2005 (ast) scientific article published on 01 April 2005 (en)
publication date	wds:Q81670366-1C49C62E-3D30-484E-9703-D71A93C6FF79
publication date	2005-04-01 00:00:00Z (xsd:dateTime)
author name string	wds:Q81670366-0E927F69-7C9D-450B-9E4C-4410CD161130 wds:Q81670366-E951A030-4374-4BF0-8968-4E3254212B87
author name string	C Kearon Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis
rdfs:label	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (en) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (nl)
skos:prefLabel	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (en) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (nl)
name	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (en) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (nl)
author	wds:Q81670366-17A79BCF-A94A-4AE0-9BA9-A96677857244
author	Sam Schulman
title	wds:Q81670366-DD6F30A1-8707-4180-B578-C9AEC9D6807C
title	Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients (en)
page(s)	wds:Q81670366-9A9EE4E1-4F08-4F85-AA33-F5F83BE776D5
page(s)	692-694
instance of	wds:Q81670366-463CF15E-26F3-45B1-A7EE-343C48B21A73
instance of	scholarly article
PubMed ID	wds:Q81670366-AFB72D9A-D015-44FE-BACE-1CA8BD231255
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/15842354
PubMed ID	15842354
published in	wds:Q81670366-5145B039-432B-41D6-A4A1-757B0CF74138
published in	Journal of Thrombosis and Haemostasis
issue	wds:Q81670366-70E6607A-79C3-4C99-B94A-567511D15F6A
volume	wds:Q81670366-BEF5CD0B-D15C-4E89-B666-D21D46C8EA0A
issue	4
volume	3
DOI	wds:Q81670366-8B21FDF2-27C8-4160-8E86-693FBF6023F5
DOI	http://dx.doi.org/10.1111/J.1538-7836.2005.01204.X
DOI	10.1111/J.1538-7836.2005.01204.X
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q81670366
is cites work of	Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study) New oral anticoagulants: a practical guide for clinicians Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II: rationale and design of the ORBIT-AF II registry Safety of switching from vitamin K antagonists to dabigatran or rivaroxaban in daily care--results from the Dresden NOAC registry Efficacy and safety of novel oral anticoagulants in clinical practice: a report from three centers in Sweden Secondary prevention of recurrent venous thromboembolism after initial oral anticoagulation therapy in patients with unprovoked venous thromboembolism Consistency of safety and efficacy of new oral anticoagulants across subgroups of patients with atrial fibrillation Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism Warfarin anticoagulation reversal: management of the asymptomatic and bleeding patient Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial Self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium Systematic review and network meta-analysis comparing antithrombotic agents for the prevention of stroke and major bleeding in patients with atrial fibrillation 2014 AHA/ACC Guideline for the Management of Patients With Non-ST-Elevation Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines THrombolysis for Acute Wake-up and unclear-onset Strokes with alteplase at 0·6 mg/kg (THAWS) Trial New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation With Direct Oral Anticoagulants. Is One Of These Not Like The Others? Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. The international, prospective Glanzmann Thrombasthenia Registry: treatment modalities and outcomes of non-surgical bleeding episodes in patients with Glanzmann thrombasthenia Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention o New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism The Swiss cohort of elderly patients with venous thromboembolism (SWITCO65+): rationale and methodology Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis Nonvitamin K antagonist oral anticoagulant activity: challenges in measurement and reversal Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. The quality of warfarin prescribing and monitoring in Veterans Affairs nursing homes Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Re-initiation of dabigatran and direct factor Xa antagonists after a major bleed Vitamin K1 supplementation to improve the stability of anticoagulation therapy with vitamin K antagonists: a dose-finding study Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2 , CHA2 DS2 -VASc, R2 CHADS2 , HAS-BLED, ATRIA, and more). Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial The effect of low molecular weight heparin on survival in cancer patients: an updated systematic review and meta-analysis of randomized trials VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines Hemostasis in patients with acute kidney injury secondary to acute liver failure Use and outcomes associated with bridging during anticoagulation interruptions in patients with atrial fibrillation: findings from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF). Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-analysis Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation--a real patient data analysis in a Hong Kong teaching hospital Heparin-induced thrombocytopenia: reducing misdiagnosis via collaboration between an inpatient anticoagulation pharmacy service and hospital reference laboratory CATCH: a randomised clinical trial comparing long-term tinzaparin versus warfarin for treatment of acute venous thromboembolism in cancer patients Genetic testing before anticoagulation? A systematic review of pharmacogenetic dosing of warfarin Efficacy and safety of low-dose clopidogrel in Japanese patients after drug-eluting stent implantation: a randomized pilot trial Low molecular weight heparin for the treatment of retinal vein occlusion: a systematic review and meta-analysis of randomized trials Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Haemorrhagic complications of vitamin k antagonists in the elderly: risk factors and management Venous thromboembolism in patients with diabetes mellitus Antiplatelet treatment compared with anticoagulation treatment for cervical artery dissection (CADISS): a randomised trial

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software